Acute myeloid leukemia – strategies and challenges for targeting oncogenic Hedgehog/GLI signaling

Fritz Aberger 1*, Evelyn Hutterer 2,3, Christina Sternberg 1, Pedro J. del Burgo 1 and Tanja N. Hartmann 2,3*

Abstract

Treatment of acute myeloid leukemia (AML), an aggressive and heterogeneous hematological malignancy, remains a challenge. Despite advances in our understanding of the complex genetics and biology of AML pathophysiology, these findings have not been translated to the clinic with only limited success, and poor outcomes persist for the majority of patients. Thus, novel treatment strategies are clearly needed for achieving deeper and prolonged remissions and for avoiding the development of resistance. Due to its profound role in (cancer) stem cell biology and differentiation, the Hedgehog (HH)/Glioma-associated Oncogene Homolog (GLI) signaling pathway may be an attractive novel therapeutic target in AML. In this review, we aim to provide a critical and concise overview of the currently known potential and challenges of HH/GLI targeting. We describe the biological role of the HH/GLI pathway in AML pathophysiology. We specifically focus on ways of targeting non-canonical HH/GLI signaling in AML, particularly in combination with standard treatment regimens, which may overcome some hurdles observed with approved HH pathway inhibitors in solid tumors.

Keywords: Acute myeloid leukemia, Cancer stem cells, Hedgehog (HH) signaling, GLI proteins, Non-canonical Hedgehog/GLI signaling, Combination therapy

Background

Acute myeloid leukemia (AML) is an aggressive hematological neoplasm with a highly diverse clinical course. Known prognostic factors include age, complex karyotype, mutations, presence of elevated white blood cell counts, antecedent hematologic disease, and prior chemo/radiotherapy for another malignancy [1]. With the advent of newer technologies such as next generation sequencing, the prognostic relevance of specific mutations and karyotypes is becoming more and more recognized and is reflected in the current revision of the AML classification of the World Health Organization (WHO) [2]. The 2016 revision updates the prior classification in an attempt to incorporate new clinical, morphological, immunophenotypic, cytogenetic and molecular genetic markers that have emerged in recent years. In contrast, in the older French-American-British (FAB) criteria, the classification of AML is solely based upon morphology, i.e. the degree of cell differentiation and maturation [3]. Moreover, the FAB classification used a cut-off of ≥ 30% blasts in the blood or bone marrow (BM) for AML diagnosis, which was adapted by the WHO to ≥ 20% since several studies reported a similar prognosis in terms of survival for patients with 20–29% blasts as for those with ≥ 30% blasts in the BM [4–8].

In order to be successful, AML treatment mainly requires management of the BM and systemic disease. Therefore, AML therapy is based on systemic combination chemotherapy and usually includes two treatment phases: firstly, the achievement of remission (induction) and secondly, the consolidation of remission. Current treatment for previously untreated AML in fit/younger patients is composed of two therapeutics, cytarabine (Ara-C) and an anthracycline such as daunorubicin (“7 + 3 induction therapy”), with a complete response/remission (CR) rate of about 65% [9]. This can optionally
be accompanied by thioguanine [10], although due to only little available data it is not possible to infer a superiority of this extended combination. Another optional addition is etoposide [11], which might prolong the duration of the initial response. Moreover, different forms and doses of anthracycline can influence the treatment outcome, so it was found that in younger patients idarubicin is more effective than daunorubicin, however, the doses tested have not been the same [9, 12–14] and no significant survival benefit was found [15].

A randomized study by the Eastern Cooperative Oncology Group (ECOG) showed that after only a short term CR all patients without consolidation chemotherapy relapsed [16] and only few successful chemotherapy regimens without relapse after a single treatment cycle have been reported [17]. Therefore, a consolidation therapy after initial remission is mandatory in order to achieve a curative effect. The current efforts in consolidation therapy comprise relatively short and intense or higher doses of chemotherapy with regimens also used in initial treatment as well as autologous or allogeneic hematopoietic stem cell (HSC) transplantation after BM chemoradiation/ablative therapy [18].

Older or unfit patients, however, often do not endure a high dose remission initiating treatment. Thus, those patients benefit more from receiving low-dose Ara-C [19] or hypomethylating agents like decitabine and azacitidine (5-Aza), which was initially approved for treatment of myelodysplastic syndrome (MDS) [20, 21]. Preliminary data from a recent phase III trial showed comparable overall survival for patients older than 65 years receiving either 5-Aza, conventional therapy of best supportive care or the 7 + 3 induction therapy [22].

Despite achievement of CR after initiation/consolidation therapy the majority of AML patients eventually relapse, either due to a lack of response or the development of drug resistance. Thus, relapsed/refractory AML (rrAML) is rather common and unfortunately very difficult to manage due to limited availability of effective therapies [23]. Currently, treatment of rrAML, depending on the patient’s fitness, includes non-/intensive chemotherapy regimens and/or HSC transplantation as well as a combination of investigational agents and high dose Ara-C, often also the enrollment in clinical trials [24]. However, standard AML treatment has not seen many modifications within the last decades and new therapeutic approaches are needed, especially for unfit patients and those with negative prognostic factors, which is highly challenging considering the heterogeneity of the various prognostic and molecular AML subgroups. This need is reflected in the numerous new treatment options presently under development and in clinical trials including combination approaches, novel formulations of cytotoxic chemotherapy and hypomethylating agents as well as other epigenetic modifiers, antibody-drug conjugates and molecularly targeted agents like cell cycle and signaling inhibitors [25–27].

Moreover, since there is increasing evidence that levels of minimal residual disease (MRD) after induction therapy are a relevant risk factor, the monitoring of MRD during remissions has already entered the clinical trial stage in AML [28]. In the long term, it is likely that the introduction of MRD assessments will provide early end points in clinical trials and thus will modify the clinical landscape. However, to achieve this goal, standardization and harmonization processes of MRD detection methods and assays are required [28, 29]. Increasing the knowledge of the cellular MRD composition might also help in identifying relapse initiating cell types, which we will further discuss in the next section.

**AML biology and the cancer stem cell concept**

AML is based on a differentiation defect of hematopoietic stem and progenitor cells (HSPCs) in the BM, resulting in accumulation of immature blast cells that displace the normal hematopoietic system. Within the BM microenvironment, AML blasts interact and communicate with stromal and immune cells, thereby impacting on the pathogenesis of the disease. In particular, leukemic blasts create their own protective niche by reprogramming mesenchymal stromal cells to selectively support leukemic cells, while simultaneously suppressing the normal hematopoiesis [30]. A common belief is that in AML a hierarchy of cells exists, with the most primitive types of cells residing in a quiescent state and protected in the leukemic niche representing the “leukemia initiating cells” or “cancer stem cells”. These cells are highly resistant to most chemotherapeutic drugs that mainly target cycling cells, and often give rise to MRD, which ultimately causes relapses [31, 32]. In a novel modification of this concept, the existence of pre-leukemic stem cells is also discussed [33, 34].

Stem cell pathways such as Wnt, Notch or Hedgehog (HH)/GLI signaling have been implicated in cellular self-renewal and resistance to chemotherapy of various cancer stem cell types [35].

The recent approval of small molecule inhibitors of HH/GLI signaling for the treatment of advanced and metastatic non-melanoma skin cancer has sparked high expectations that HH/GLI targeting may prove an efficient and even curative therapeutic approach for a range of solid and hematological malignancies [36–38]. However, several recent clinical trials have largely failed to demonstrate a therapeutic benefit of HH/GLI inhibitors that target the essential pathway effector Smoothened (SMO) in a variety of solid cancer entities [39]. These disappointing trial data dampened the enthusiasm of the field for treating HH-associated cancers by blocking SMO function but at the same time opened up new
therapeutic strategies concentrating on the targeted inhibition of the critical oncogenic downstream HH effectors, the GLI zinc-finger transcription factors. There is substantial preclinical evidence that inhibition of SMO-independent GLI activation (henceforth referred to as non-canonical HH/GLI signaling) may provide a pronounced therapeutic benefit, also in settings with acquired or a priori resistance to SMO inhibitors [40–44].

In the following chapters, we aim to provide a concise overview of recent studies addressing the role of HH/GLI signaling in AML pathogenesis and its possible therapeutic implications. We summarize selected key mechanisms of non-canonical HH/GLI signal transduction, concentrating on novel insights into SMO-independent regulation of GLI activity by multiple oncogenic signal cues. Based on these cross-talk signaling events, we discuss possible therapeutic approaches tackling AML by targeting oncogenic GLI proteins with novel compounds and rational combination treatments.

**HH/GLI signaling in AML biology and therapy**

With regard to AML biology and pathogenesis, the HH pathway has recently received much attention for its implication in leukemic stem cell regulation and in the orchestration of acquired drug resistance of poor prognostic AML (summarized in Fig. 1). Using modified human myeloid cell lines (HL60), Li and colleagues [45] showed that myeloid cells that acquired radio- (HL60/RX) as well as drug-resistance (HL60/ADR) express higher levels of SMO and GLI1. In line, the radioresistance was overcome by inhibition of the HH pathway via the SMO antagonist LDE225 (sonidegib/erismodegib).

![Fig. 1 Model of oncogenic HH/GLI signaling in AML.](image)

Activation of HH/GLI in leukemic (stem) cells of AML patients can be activated by HH ligand derived from adjacent BM stromal cells expressing low levels of the HH inhibitor HHIP. GLI expression in AML cells can enhance radio- and chemo resistance, and promote leukemogenesis by epigenetically repressing cell-cycle inhibitors (e.g. p15) or by synergistic cross-talk with oncogenic FLT3/STAT5 signaling. LIC: leukemia initiating cell; Me: DNA methylation.
involving a cross-talk with and down-regulation of the GLI1/P13K/AKT/ NF-κB pathway. Thus, LDE225 treatment resulted in increased apoptosis induction and decreased DNA repair ability upon radiation.

Further evidence for an involvement of HH/GLI signaling in drug resistance was provided by Zahreddine et al. who analyzed primary tumor samples of patients that relapsed after monotherapy with ribavirin (an inhibitor of the eukaryotic translation initiation factor eIF4E) [46]. The authors observed an association of relapse and drug resistance with elevated levels of GLI1 and the UDP glucuronosyltransferase (UGT1A), which can inactivate ribavirin by glucuronidation, thus preventing binding of this drug to its target eIF4E. GLI alone was sufficient to drive the expression of UGT1A and accounted for drug glucuronidation. Accordingly, in vitro treatment of patient samples with previously failed induction therapy with the SMO inhibitor vismodegib (GDC-0449) potentiated the effects of cytarabine and ribavirin, providing a rationale for combination of HH inhibitors with conventional treatment regimes. Currently, a clinical trial using ribavirin and vismodegib with or without decitabine in AML is in the recruitment phase (clinical trial number NCT02073838). Patients with AML M4 or M5 FAB subtype or high eIF4E are eligible. All patients must have failed primary therapy (defined as two induction chemotherapies), must have relapsed, or must not be suitable candidates for intensive induction chemotherapy.

In addition, HH/GLI targeting also bears potential for those patients that do not tolerate aggressive therapeutic regimes. In particular, a combination of these antagonists with 5-Aza can be envisaged. Tibes and colleagues conducted an RNA interference sensitizer screen to identify gene targets of distinct regions presumably enhancing 5-Aza therapy [47]. Several HH pathway molecules could be identified, among them SMO, which was subsequently evaluated as a therapeutic target in vitro using seven heterogeneous AML cell lines. In these assays, the authors identified cytotoxic synergy of LDE225 and vismodegib with 5-Aza.

In fact, several clinical trials using SMO inhibitors alone or in combination with compounds blocking driver mechanisms in AML have already been initiated. For instance, the potency of the SMO inhibitor glasdegib (PF-04499913) alone or in combination with e.g. 5-Aza or chemotherapy is being investigated in several clinical trials for hematologic malignancies including MDS and AML (http://clinicaltrials.org, NCT01842646, NCT01841333, NCT01546038, NCT02367456). It is noteworthy that in a phase 2 trial with untreated AML and high-risk MDS patients, low dose Ara-C chemotherapy in combination with glasdegib improved overall survival when compared to chemotherapy only [48]. The community is keenly awaiting the outcome of these trials, also in light of the discussion of SMO-dependent and independent regulation of oncogenic GLI activity.

Indeed, besides targeting SMO, direct inhibition of GLI is a promising option, particularly in settings of SMO-independent GLI activation. On basis of two comprehensive clinical patient cohorts, a significant negative prognostic impact of GLI2 expression in AML could be established by Wellbrock and colleagues [49]. In the first cohort, based on the AMLSG 07–04 trial comprising 104 patient samples, the presence of GLI2 expression significantly shortened event-free survival, relapse-free survival, and overall survival and was correlated with FLT3 mutational status. Analysis of a second, independent cohort of 290 AML samples confirmed the negative impact of GLI2 on event-free survival and overall survival.

The relevance of GLI expression for disease pathogenesis was further strongly supported by in vitro and in vivo experimental data using treatment of AML cell lines by GANT61, a GLI antagonist tool compound [50], and GLI shRNA approaches as well as an adoptive transfer model of AML. Of note, mice transplanted with GLI1/GLI2 double-depleted AML cells displayed a moderate yet significant increase in survival compared to controls. These data clearly support the development of clinically useful GLI antagonists for therapy.

Further support for an association of FLT3-mutated AML and HH pathway activation via the STAT pathway has recently been provided by the Matsui group [51] using transgenic mouse models with a combination of constitutively active SMO and internal tandem duplications (ITD) of FLT3. Combined treatment using the SMO inhibitor saridegib/IPI-926 and the kinase inhibitor sorafenib resulted in reduced tumor load and increased survival of the mice. The clinical impact was further supported by the identification of increased GLI2 expression in FLT3-ITD positive AML patients.

In tumor cells, both autocrine and paracrine HH pathway activation via the STAT pathway has been described [52]. In AML, in contrast to some solid tumors, the microenvironment appears to play the dominant role in providing such activation inducing ligands to leukemic cells. Wellbrock and colleagues [49] observed that AML patients displayed increased serum levels of Desert Hedgehog (DHH) that was obviously produced and shed into the blood by the BM microenvironment rather than the AML cells. Similar observations have been made by other authors, reporting an increased expression of Sonic Hedgehog (SHH), SMO, and GLI1 in BM stromal cells of MDS patients, compared to healthy donors that are known to express Indian Hedgehog (IHH) and SMO [53], with even higher HH effector levels in post-MDS AML [54].
Human Hedgehog-interacting protein (HHIP), a glycoprotein binding to and thus inhibiting HH ligand function, is produced by healthy BM stromal cells and has been shown to have the potential of suppressing proliferation of leukemic cells. In contrast, HHIP expression in BM stromal cells derived from AML and MDS patients was reduced [55], which was accompanied by the ability of these cells to support leukemic cell proliferation. This reduced HHIP expression might thus contribute to the progression of AML and MDS. Moreover, pretreatment with 5-Aza induced demethylation of the HHIP gene and partial restoration of HHIP expression, thereby reducing the supportive effect of the primary AML/MDS stromal cells on the malignant cells and underlining the function of HHIP as an endogenous HH ligand inhibitor.

More recently, GLI1 expression has been shown to correlate with increased expression of DNA methyltransferase 1 (DNMT1) and high-risk MDS. Of note, knock-down of GLI1 in MDS cells not only decreased survival, proliferation and DNMT1 expression but also enhanced the demethylating efficacy of 5-Aza, resulting in lower methylation of the tumor suppressor gene p15 promoter and enhanced p15 expression, respectively [56]. Combined use of GLI antagonists with demethylating drugs may therefore show improved therapeutic efficacy.

In line with an oncogenic role of HH/GLI in MDS and AML, a positive correlation between GLI1 expression and percentage of AML blasts, as defined by CD34 expression, has recently been observed in BM [57]. Also in the cell lines used in this study, in vitro treatment with the GLI antagonist GANT61 resulted in reduced proliferative and colony forming characteristics and displayed synergistic cytotoxicity with Ara-C [57].

**The potential of targeting non-canonical HH/GLI signaling in AML**

While canonical activation of the GLI transcription factors depends on activation of the essential pathway effector SMO either by ligand-dependent or genetic inactivation of the HH receptor Patched (PTCH) (Fig. 2)
(reviewed in [58–61]), non-canonical regulation of GLI transcription factors is independent of SMO activation, and can be mediated by a variety of distinct key oncogenic signaling cascades [44, 62, 63]. This has important therapeutic implications, as SMO-independent GLI activation results in SMO inhibitor resistance, a clinically relevant problem that may account for the disappointing results from several trials using SMO inhibitors (e.g. vismodegib, sonidegib, saridegib) [39, 64]. Further, the severity of adverse effects induced by SMO inhibitors (e.g. muscle cramps) limits the prolonged administration of such drugs [65, 66]. We therefore propose that direct targeting of oncogenic GLI transcription factors, as has been shown in several proof of concept studies [50, 67, 68], in combination with strategies interfering with oncogenic cues promoting GLI activity in AML will provide a therapeutic benefit compared to single treatment protocols (Fig. 3).

In the following section, we will provide an overview of mechanistic models that can account for SMO inhibitor resistance and will summarize several representative and seminal studies that have revealed SMO-independent positive or negative regulation of GLI activity by oncogenic signaling pathways and epigenetic factors (reviewed in [44, 69]). Given the critical role of GLI transcription factors in the development and progression of several leukemic diseases including AML, a detailed understanding of “druggable” cross-talk pathways controlling oncogenic GLI function will provide the rationale for the design and evaluation of novel, efficacious combination treatments in AML.

Oncogenic signals regulating GLI activity

The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK signaling cascades control multiple cellular functions such as transcription, translation, proliferation, growth and survival. The aberrant activation of these oncogenic signals plays major roles in numerous malignant entities and therapeutic targeting of PI3K/AKT/mTOR and MEK/ERK signaling is a promising approach, intensely tested in clinical trials using selective small-molecule inhibitors (reviewed in [70–72]). Cross-talk of HH signaling with both PI3K/AKT and RAS/RAF/MEK pathways has been described in many cancer entities including melanoma, prostate cancer, non-melanoma skin cancer, glioma and leukemia. For instance, the cross-talk of HH/GLI and PI3K/AKT has an impact on GLI1 and GLI2 expression, protein stability, nuclear localization and transcriptional activity [73–80].

Another study dealing with human pancreatic cancer revealed an inhibitory effect on tumorigenic cancer stem cells through the combined blockade of HH and mTOR signaling using SMO and mTOR inhibitors together with standard chemotherapy [81]. These findings were supported by Miyazaki et al. who described that combined inhibition of HH and mTOR signaling eliminates...
pancreatic cancer stem cells. In contrast to the previously mentioned study, they used the direct GLI antagonist GANT61, which had a stronger negative effect on sphere formation and cell viability than the SMO inhibitor cyclopamine, even in the absence of additional standard chemotherapy [82].

Moreover, the signal integration of non-canonical GLI1/2 activation by PI3K/AKT was also deciphered as a novel potential therapeutic target because combination of the GLI inhibitor GANT61 and the AKT inhibitor perifosine resulted in synergistically suppressed tumor growth and induced apoptosis in renal cell carcinoma models [73]. Recently, Kern and colleagues reported a synergistic therapeutic effect in cells from a subgroup of CLL patients through combined targeting of GLI and PI3K/AKT/mTOR signaling [83]. Moreover, GLI1 protein can be phosphorylated by the ribosomal S6-kinase 1 (S6K1), a critical downstream effector of PI3K/AKT and MEK/ERK signaling. Notably, mTOR/S6K1-mediated phosphorylation appears to facilitate the release of GLI1 protein from its cytoplasmic repressor SUFU, thereby enhancing the overall oncogenicity of GLI1 in esophageal adenocarcinoma cells. In line with these mechanistic findings, combined inhibition of HH/GLI and mTOR/S6K1 activity synergistically reduced the survival of GLI expressing esophageal cancer cells [84]. Taken together, these studies support a pronounced therapeutic benefit of combined HH/PI3K/mTOR targeting in selected malignant diseases. Whether similar cooperative mechanisms operate in AML pathogenesis remains to be addressed.

GLI transcriptional activity is also positively regulated by RAS/RAF/MEK/ERK signaling, for instance in melanoma and pancreatic cancer [76, 85, 86]. Mechanistically, direct phosphorylation of GLI proteins by ERK kinases can enhance transcriptional GLI activity [86, 87]. Cross-talk of epidermal growth factor receptor (EGFR) signaling with HH/GLI also depends on MEK/ERK activation, yet involves another mechanism of cooperation. HH/EGFR signal integration relies on cooperativity of selected transcription factors simultaneously induced by concomitant HH/EGFR signaling. These studies revealed that EGFR can synergize with HH/GLI via MEK/ERK-dependent activation of JUN/AP-1 transcription factors, resulting in synergistic induction of common HH/EGF target genes and oncogenic transformation [78–80].

Additional druggable kinases modulating oncogenic GLI activity include atypical Protein Kinase C (aPKC or PKC iota/gamma) and members of the dual-specificity tyrosine phosphorylation regulated kinase (DYRK) family. aPKC has been shown to directly phosphorylate GLI1 at amino acid residues located in the zinc finger DNA binding domain, thereby enhancing DNA binding and maximum transcriptional activity of GLI. Notably, SMO inhibitor resistance can be mediated by hyperactivation of aPKC, suggesting that aPKC targeting in patients unresponsive to SMO inhibitors may overcome SMO inhibitor resistance, as shown in in vitro models [42, 88]. DYRK kinases can exert positive or negative effects on the transcriptional activity of GLI. DYRK1A-mediated phosphorylation of GLI1 can increase GLI1 activity by promoting its nuclear localization [89]. Recently, our own group has provided evidence for a critical positive role of DYRK1B rather than DYRK1A in various human cancer entities and shown that genetic and pharmacologic DYRK1B targeting can efficiently eliminate GLI1-dependent tumor-initiating pancreatic cancer cells [90].

Aside from this, a KRAS/DYRK1B network can also redirect autocrine HH signaling towards a paracrine mode in human pancreatic adenocarcinoma [91]. Unlike DYRK1 proteins, DYRK2 represses GLI activity by promoting proteasomal degradation of GLI2 via direct phosphorylation [92]. Pharmacologic inhibition of oncogenic GLI proteins therefore requires clinically useable drugs that selectively target DYRK1 family members.

Casein kinase 1-alpha (CK1A) and protein kinase A (PKA) can be considered additional potential therapeutic targets. Activation of CK1A by pyrvinium can promote GLI repressor formation and GLI degradation [93]. However, as CK1A can also be an activator of HH signaling, its overactivation has to be taken with precaution [94]. Activation of PKA for instance by imiquimod, a synthetic nucleoside analog that binds to adenosine receptors, induces GLI phosphorylation and subsequent degradation and/or cleavage into repressor forms [95].

In addition to phosphorylation, other post-translational modifications of GLI proteins control the oncogenic activity of GLI. Canettieri et al. have shown that acetylation of GLI1 and GLI2 represses, while histone deacetylase (HDAC)-mediated deacetylation increases their transcriptional activity. This interplay is further regulated by a positive feed-forward loop involving HH-induced upregulation of HDAC1 [96]. The role of HDACs in promoting HH/GLI signaling has been further supported by findings showing that HDAC6 activity is required for the full-activation of HH/GLI signal strength [97]. The use of selected clinically validated HDAC inhibitors, which have already shown promising therapeutic efficacy in AML patients [98], in combination with GLI antagonists may therefore be an attractive therapeutic approach in GLI-dependent cancer entities. The finding that a novel dual HDAC/SMO inhibitor, NL-103, can down-regulate both HH/GLI and HDAC activity, thereby overcoming vismodegib resistance [99], exemplifies that dual targeting of GLI and GLI promoting signals such as HDACs with a single compound is feasible and an attractive option for future therapeutic strategies including the treatment of AML patients.
As another epigenetic regulator of HH/GLI, the BET family member bromodomain 4 (BRD4) protein has been shown to modulate HH signaling. BRD4 can bind to acetylated lysines in histones, enhance target gene expression via stimulation of RNA polymerase II activity and can be efficiently inhibited by the BRD antagonists JQ1 and I-BET [100, 101]. BRD4 activity has been linked to HH/GLI signaling in two parallel studies showing that BRD4 regulates GLI transcription in a SMO- and SUFU-independent manner by binding directly to the GLI1 and GLI2 promoters and that JQ1 reduces the binding of BRD4 to its binding sites in the GLI promoters [101, 102]. Intriguingly, JQ1 also inhibits BRD4-regulated MYC activity [103], a critical driver signal in AML pathogenesis. The impressive therapeutic activity of BRD inhibitors in preclinical models of AML may therefore result from their inhibitory effect on multiple targets including key oncogenic players in leukemic (stem) cells such as MYC and GLI [104–107].

Conclusions

In summary, the still very high occurrence of AML relapses upon therapy reflects the need for novel treatment strategies. In this regard, targeting the HH/GLI pathway in AML can be a promising therapeutic approach, since this signaling cascade is crucially involved not only in the regulation of cancer stem/leukemia initiating cells, but also in the development of drug resistance. The possibility of inhibiting multiple key players in this pathway (i.e. SMO, GLI1/GLI2) as well as the combination with other agents targeting important mechanisms involved in AML pathology (e.g. kinase inhibitors and epigenetic regulators such as 5-Aza, HDACi and BRD4) provide a multitude of new treatment options. Targeting the non-canonical HH/GLI signaling pathway by directly interfering with the activity of the GLI transcription factors as well as their cross-talk with other signaling pathways (e.g. kinases) may be particularly promising, since this alternate approach might prevent the development of resistance and severe side effects as seen for SMO inhibitors.

Abbreviations

5-Aza: Azacitidine; AML: Acute myeloid leukemia; aPKC: Atypical Protein Kinase C; Ara-C: Cytarabine; BM: Bone marrow; BRD4: BET family member bromodomain 4; CK1A: Casein kinase 1-alpha; CR: Complete response/remission; DNMT1: DNA methyltransferase 1; Dyrk: Dual-specificity tyrosine phosphorylation regulated kinase; ECOG: Eastern Cooperative Oncology Group; EGFR: Epidermal growth factor receptor; elf4E: Eukaryotic translation initiation factor 4E; FAB: French-American-British; GLI1: Glioma-associated Oncogene Homolog; HDAC: Histone deacetylase; HH: Hedgehog; HHIP: Hedgehog-interacting protein; HSC: Hematopoietic stem cell; HSPCs: Hematopoietic stem and progenitor cells; IHF: Indian Hedgehog; ITD: Internal tandem duplications; MDS: Myelodysplastic syndrome; MRD: Minimal residual disease; PAK: Protein kinase A; PTCH: Patched; rrAML: Relapsed/refractory AML; SHH: Sonic Hedgehog; SMO: Smoothened; UGT1A: UDP glucuronosyltransferase; WHO: World Health Organization

Acknowledgements

The authors gracefully acknowledge financial support by the Austrian Science Fund (FWF), projects P25629 and W1213, the priority program "Allergy-Cancer-Bionano Research Center" of the Paris-Lodron University of Salzburg, the cancer research and trans4tech initiatives of the county of Salzburg and by the Province of Salzburg.

Funding

Austrian Science fund (FWF) W1213 to FA and TNH, P25629 to FA;

Availability of data and material

Not applicable.

Authors’ contributions

EH, CS and PJDB performed literature research and wrote the manuscript. FA and TNH conceived, refined, revised and wrote the manuscript and designed the figures. All authors read and approved the final manuscript.

Authors’ information

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Author details

1Cancer Cluster Salzburg, Department of Moleculer Biology, Paris-Lodron University of Salzburg, Hellbrunner Strasse 34, 5200 Salzburg, Austria. 2Cancer Cluster Salzburg, Salzburg Cancer Research Institute (SCRI) - Laboratory for Immunological and Molecular Cancer Research (LIMCR), 5200 Salzburg, Austria. 3Third Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Disease and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Müllner Hauptstrasse 48, 5200 Salzburg, Austria.

Received: 1 December 2016 Accepted: 18 January 2017

Published online: 25 January 2017

References

1. Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373:1136–52.
2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
3. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Bruning R, Gale RP, Grever MR, Keating MJ. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:1318–9.
4. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003;27:95–120.
5. Huh YO, Jilani I, Estey E, Giles F, Kantarjian H, Freireich E, Albitar M. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. Leukemia. 2002;16:2249–52.
6. Greenberg P, Anderson J, de Witte T, Estey E, Fenaux P, Gupta P, Hamblin T, Hellstrom-Lindberg E, List A, Muffi G, Neuwiotova R, Ohyashiki K, Osiier D, Sanz G, Sanz M, Willman C. Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol. 2002;20:3447–52.
7. Estey E, Thull P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997;90:2969–77.
8. Strupp C, Gattermann N, Giagounidis A, Aul C, Hildebrandt B, Haas R, Germain U. Refractory anemia with excess of blasts in transformation:
analysis of reclassification according to the WHO proposals. Leuk Res. 2003;27:397–404.

9. Wiernik PH, Banks PL, Case DC, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79:313–9.

10. Buchner T, Hiddemann W, Berdel WE, Wormann B, Schoch C, Fonatsch C, Loeffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staub P, Aul C, Grunisen A, Lengfelder E, Frichkohn N, Kern W, Serve H, Mesters RM, Sauerland MC, Heinecke A, German AMLGCG 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol. 2003;21:4496–504.

11. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R, Whiteside MG, Konoshima H, Ma D, Dodds A. Etoposide in acute non-lymphocytic leukaemia. Australian Leukaemia Study Group. Blood. 1990;75:27–32.

12. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bouchillon AA, Omura GA, Gerber MC, Banks PL. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southwestern Cancer Study Group Study. J Clin Oncol. 1992;10:103–11.

13. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreffe M, Kolitz J, Gabrilove J. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77:1666–74.

14. Mandelli F, Petiti MC, Ardia A, Di Pietro N, Di Raimondo F, Ganzani F, Falconi E, Gareri E, Ladogana S, Latagliata R. A randomized clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukemia. A multicentric study from the Italian Co-operative Group GIMEMA. Eur J Cancer. 1992;27:50–5.

15. Arlin Z, Case DC, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K. Randomized multilocore center trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia Cooperative Group. Leukemia. 1990a;4:177–83.

16. Cassileth PA, Harrington DP, Hines JD, Oken MM, Mazza JJ, McGlave P, Bennett JM, O’Connell MJ. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol. 1988;6:583–9.

17. Vaughan WP, Karp JE, Burke PJ. Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelogenous leukemia. Cancer. 1980;45:859–65.

18. Short NJ, Ravandi F. Acute Myeloid Leukemia: Past, Present, and Prospects for the Future. Clin Lymphoma Myeloma Leuk. 2016;16(Suppl):S52–9.

19. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Loffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Enck RE, Weitberg AB. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia: a randomized controlled trial of the International AML Cooperative Group. J Clin Oncol. 2002;20:2429–40.

20. Itzykson R, Thépot S, Berthon C, Deleuvaux N, Joubert S, Adès L, Ifrah N, Dombert H, Fenaux P, Gardin C. Azacitidine for the treatment of relapsed and refractory AML in older patients. Leuk Res. 2015;39:124–30.

21. Kelly J. Considerations and challenges for patients with refractory and relapsed acute myeloid leukemia. Leuk Res. 2016;47:1–90.

22. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Myeloid Leukemia (Version 2.2016) [https://www.nccn.org/professionals/pharmacists/guidelines/pdf/aml.pdf]

23. Shaffer D, Grant S. Update on rational targeted therapy in AML. Blood Rev. 2016;30:275–83.

24. Stein EM, Tallman MS. Emerging therapeutic drugs for AML. Blood. 2016;127:71–8.

25. Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127:53–61.

26. Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”? Blood. 2014;124:3345–55.

27. Ossenkoppele G, Schuurhuis GJ. MRD in AML: does it already guide therapy decision-making? Hematology Am Soc Hematol Educ Program. 2016;2016:355–65.

28. Kim JA, Shin JS, Lee YG, Yim HW, Kim TM, Kim M, Leem SH, Lee JW, Min CK, Oh IH. Microenvironmental remodeling as a parameter and prognostic factor of heterogeneous leukemogenesis in acute myelogenous leukemia. Cancer Res. 2015;75:2222–31.

29. Dick JE. Acute myeloid leukemia stem cells. Ann N Y Acad Sci. 2005;1044:1–5.

30. Carlson KS, Guzman ML. Is minimal residual disease monitoring clinically relevant in adults with acute myelogenous leukemia? Curr Hematol Malig Rep. 2013;8:109–15.

31. Dick JE. Acute myeloid leukemia stem cells. Ann N Y Acad Sci. 2005;1044:1–5.

32. Carlson KS, Guzman ML. Is minimal residual disease monitoring clinically relevant in adults with acute myelogenous leukemia? Curr Hematol Malig Rep. 2013;8:109–15.

33. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, Kennedy JA, Schimmer AD, Schuh AC, Kew YW, McLeod JL, Doedens M, Medeiros JJ, Markes R, Kim HI, Lee K, McPherson JD, Hudson TJ, Brown AM, Yousif F, Trinh QM, Stein LD, Minden MD, Wang JC, Dick JE. Identification of pre-leukaemic haematopoietic stem cells in acute myelogenous leukemia. Nature. 2014;506:328–33.

34. Cores-Zimmermann MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A. 2014;111:2548–53.

35. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2011;8:97–106.

36. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, Low JA. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. The New England journal of medicine. 2009;361:1173–8.

37. Bajaj A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HW, Yauch RL, Graham RA, Reddy JC, Haushild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. The New England journal of medicine. 2012;366:2171–9.

38. Tang JY, Mackay-Wiggan JM, Asztérrbaum M, Yauch RL, Lindgreen J, Chang K, Coppola C, Chanana AM, Tijl J, Bickers DR, Epstein Jr EH. Inhibiting the hedgehog pathway in patients with basal-cell nevus syndrome. The New England journal of medicine. 2012;366:2180–8.

39. Pak E, Segal RA. Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy. Dev Cell. 2016;38:333–44.

40. Yauch RL, Dijkstra GF, Aliche B, Jani A, Mason TP,Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009;326:572–4.

41. Buonanunci S, Williams J, Morrissey MJ, Wang A, Guo RV, Vattay A, Hsiao S, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JE, Beesley P, Pan S, Wu K, Maira SM, Garcia-Echeverria C, Briggs K, Watkins DN, Yeo VM, Lengauer C, Warmuth M, Sellers WR, Dorsch M. Interfering with resistance to smoothened pathway in gliomas. Cancer Cell. 2010;17:211–21.

42. Atwood SX, Li M, Lee A, Tang JY, Oro AE. GlI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas. Nature. 2013;494:484–8.
43. Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, Tsui V, Durham AB, Dlugosz AA, Havery PM, Bourgon R, Tang JY, Sarin KY, Dirix L, Fisher DC, Rudin CM, Sofen H, Migden MR, Youch RL, de Sauvage FJ. Genomic analysis of streamlined inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015;27:327–41.

44. Aberger F, Ruiz i Altaba A. Context-dependent signal integration by the GLI code: the oncogenic load, pathways, modifiers and implications for cancer therapy. Semin Cell Dev Biol. 2014;33:93–104.

45. Li X, Chen F, Zhu Q, Ding B, Zhong Q, Huang K, Jiang X, Wang Z, Yin C, Zhu Y, Li Z, Meng F. GLI-1/Pi3K/AKT/NF-kB pathway mediates resistance to radiation and is a target for reversion of responses in refractory acute myeloid leukemia cells. Oncotarget. 2016;7:33004–15.

46. Zahreddine HA, Cukovic-Kraljacic B, Assolline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cericelli L, Cocolakis E, Amri A, Bergeron A, Leber B, Becker MW, Pei S, Jordan CT, Miller WH, Borden KL. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature. 2014;511:90–3.

47. Tilles R, Al-Kali A, Oliver GR, Delman DH, Hansen N, Bhagavatula K, Mohan J, Rakhsah F, Wood T, Foran JM, Mesa RA, Bogenberger JM. The Hedgehog pathway as targetable vulnerability with S-azacitidine in myelodysplastic syndrome and acute myeloid leukemia. J Hematol Oncol. 2015;8:114.

48. Cortes JE, Heidel FH, Heuser M, Fiedler W, Smith BD, Robak T, Krauter J, Fiedler W. Expression of Hedgehog Pathway Mediator GLI1/DNA interaction is a druggable target for Hedgehog-dependent tumours. EMBO J. 2015;34:2001–17.

49. Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and MEK2 inhibitors and cancer therapy. Semin Cell Dev Biol. 2014;33:93–104.

50. Lauth M, Bergstrom A, Shimokawa T, Toftgard R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A. 2007;104:8455–60.

51. Lim Y, Gedde L, Li L, Wang Q, Ma H, Chang E, Hsu DL, Forrester S, Marchioni L, McGovern K, Watkins DN, Peacock CD, Levis M, Smith BD, Merchant AA, Small D, Matsui W. Integration of Hedgehog and mutant FLTR3 signaling in myeloid leukemia. Sci Transl Med. 2015;7:291ra296.

52. Theunissen JW, de Sauvage FJ. Paracrine Hedgehog signaling in cancer. Cancer Res. 2009;69:6907–10.

53. Kobune M, Ito Y, Kawano Y, Sasaki K, Uchida H, Nakamura K, Dehari H, Chiba H, Takimoto R, Matsunaga T, Terui T, Kato J, Nitsu Y, Harada H. Indian hedgehog gene transfer augments hematopoietic support of human stromal cells including NOD/SCID betax-m/-/- repopulating cells. Blood. 2004;104:1002–9.

54. Zou J, Hong Y, Tong Y, Wei J, Qin Y, Shao S, Wang C, Zhou K. sonic hedgehog produced by human bone marrow-derived mesenchymal stromal cells supports cell survival in myelodysplastic syndrome. Stem Cells Int. 2015;2015:975002.

55. Kobune M, Iyama S, Kitkuchi S, Horiguchi H, Sato T, Murate K, Kawano Y, Takada K, Ono K, Kamihara Y, Hayashi T, Miyashita K, Sato Y, Takimoto R, Kato J. Stromal cells expressing hedgehog-interacting protein regulate the proliferation of myeloid neoplasms. Blood Cancer J. 2012;2:e87.

56. Zou J, Zhou Z, Wan L, Tong Y, Qin Y, Wang C, Zhou K. Targeting the Sonic Hedgehog-Gli1 Pathway as a Potential New Therapeutic Strategy for Myelodysplastic Syndrome. PLoS One. 2015;10(6):e0136913.

57. Long B, Wang LX, Zheng FM, Lai SP, Xu DR, Hu Y, Lin DJ, Zhang XZ, Dong L, Long ZI, Tong ZX, Liu Q. Targeting GLI1 Suppresses Cell Growth and Enhances Chemosensitivity in CD34+ Enriched Acute Myeloid Leukemia Progenitor Cells. Cell Physiol Biochem. 2016;38:1288–302.

58. Teglund S, Toftgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochimica et biophysica acta. 1805;2010:181–208.

59. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes & development. 2001;15:3059–87.

60. Wong SY, Reiter JF. The primary cilium at the crossroads of mammalian hedgehog signaling. Curr Top Dev Biol. 2008;85:225–60.

61. Ruiz i Altaba A, Sanchez P, Dahmane N. GLI and hedgehog in cancer: tumours, embryos and stem cells. Nature reviews Cancer. 2002;3:361–72.
1. MiyaZaki Y, Matsubara S, Ding Q, Tsukasa K, Yoshimitsu M, Kosai K, Takao S. Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition. Mol Cancer. 2016;15:49.

3. Kern D, Rehl G, Hofbauer SW, Altenhofer P, Achatz G, Dlugos A, Schindl H, Greil R, Hartmann TN, Aberger F. Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia. Oncogene. 2015;34:3341–51.

6. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Hsiao L, Babb FM, Li D, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Butt NS, Wang KK, Wu Y, Wang H, Ajani J, Hung MC. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer cell. 2012;21:374–87.

8. Ji Z, Mei FC, Xie J, Cheng X. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. The Journal of biological chemistry. 2007;282:14048–55.

11. Riobo NA, Haines GM, Emerson Jr CP. Protein kinase C-delta and mitogen-activated protein/extracellular signal-regulated kinase-1 control GLI activation in hedgehog signaling. Cancer research. 2006;66:6839–45.

14. Whisenant TC, Ho DT, Benz RW, Rogers JS, Kaake RM, Gordon EA, Huang L, Wolff F, Loipetzberger A, Gruber W, Esterbauer H, Aberger F, Frischauf AM. REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling. Cell. 2008;133:537–50.

17. Varjosalo M, Bjorklund M, Cheng F, Syvanen H, Kivioja T, Klippen S, Sun Z, Kallioniemi O, Stummenberg HG, He WW, Qala P, Tapale J. Application of active and kinase-deficient kinase collection for identification of kinases regulating hedgehog signaling. Cell. 2008;133:537–48.

20. Infante P, Alonzi F, Bott A, Motti D, Di Marcolillo L. Targeting GLI factors to inhibit the Hedgehog pathway. Trends PharmacoSci. 2015;36:547–58.

23. Chen Y, Yatani M, Chong H, Liang S, Li B, Rodriguez-Blanco J, Pastori C, Volmar CH, Walehsedt C, Capobianco A, Bai F, Pei XH, Ayad NG, Robbins DJ. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers. J Biol Chem. 2014;289:35494–502.

26. Tang Y, Gholamin S, Schubert S, Willardson MJ, Lee A, Randophayadav P, Berghold G, Mascou S, Nguyen B, Vu N, Balansay B, Yu F, Soh P, Chen S, Ponnuswami A, Monje M, Atwood SX, Whitson RJ, Mura T, Cheshier SH, Qi J, Beroukhim R, Tang JY, Wechsler-Reya R, Oro AE, Link BA, Bradner JE, Cho YJ. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med. 2014;20:732–40.

29. Delmone JE, Iica GC, Lemieux ME, Rahi PB, Shi J, Jacobs HW, Kastritis E, Gilpatrick T, Panal RM, Qi J, Checi M, Schinzel AC, McKewon MR, Hefferman TP, Vakoc CR, Bergsaegel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904–17.

32. Herrmann H, Blatt K, Shi J, Gleixner KV, Cemy-Reiterer S, Mullauer L, Vakoc CR, Sperr WR, Horny HP, Bradner JE, Zuber J, Valant P. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia. Oncotarget. 2012;3:1588–99.

35. Valant P, Zuber J. BRD4: a BET(ter) target for the treatment of AML? Cell Cycle. 2014;13:689–90.

38. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valant P, Bradner JE, Lowe SW, Vakoc CR. RNAi screen identifies BRD4 as a therapeutic target in acute myeloid leukemia. Nature. 2011;478:524–8.

41. Chaidos A, Caputo V, Karadimitris A. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Ther Adv Hematol. 2015;6:128–41.